Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: Confounding effects of tolerance and implications for therapeutics

Biological Psychiatry

Volumn 41, Issue 3, 1997, Pages 264-272

  Callahan, Ann M ^a,b,g   Frye, Mark A ^a   Marangell, Lauren B ^a,c   George, Mark S ^a,d   Ketter, Terence A ^a,e   L'Herrou, Todd ^a,f   Post, Robert M ^a,h  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Electronic Village Systems   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

bipolar disorder; depression; intrathecal administration; intravenous administration; thyrotropin releasing hormone; tolerance

Indexed keywords

PROTIRELIN;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031081042     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00372-7     Document Type: Article

References (50)

1. Banki CM, Bissette G, Arato M, Nemeroff CB (1988): Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry 145:1526-1531.
2. Bassiri R, Utiger R (1973): Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest 52:1616-1619,
3. Brooks BR, Kalin N, Beaulieu DA, Barksdale C, Sufit RL, Dills DG (1988): Thyrotropin-releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. Neurol Res 10:236-238.
4. Chambers FA, MacSullivan R (1994): Intrathecal morphine in the treatment of chronic intractable pain. Ir J Med Sci 163:318-321.
5. Chi ML, Lin MT (1983): Involvement of adrenergic receptor mechanisms within hypothalamus in the fever induced by amphetamine and thyrotropin-releasing hormone in the rat. J Neurol Transm 58:213-222.
6. Coffe YJ, Cahill D, Steers W, et al (1993): Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 78:226-232.
7. Coppen A, Montgomery S, Peet M (1974): Thyrotropin-releasing hormone in the treatment of depression. Lancet i:433-435.
8. Crawley JN, Kiss JZ (1985): Paraventricular nucleus lesions abolish the inhibition of feeding induced by systemic cholecystokinin. Peptides 6:927-935.
9. Crawley JN, Schwaber JS (1983): Nucleus tractus solitarius lesions block the behavioral actions of cholecystokinin. Peptides 4:743-747.
10. Crawley JN, Hays SE, Paul SM (1981): Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. Eur J Pharmacol 73:379-380.
11. Ehrensing RH, Kastin AJ, Schalch DS, Friesen HG, Vargas JR, Schally AV (1974): Affective state and thyrotropin and prolactin responses after repeated injections of thyrotropin-releasing hormone in depressed patients. Am J Psychiatry 131:714-718.
12. Friedman T, Yanovski J, Jayasvasti V, Yanovski S, Koenig R, Wilk S (1995): Pyroglutamyl peptidase II activity in human serum: Influence of weight and thyroid status. J Clin Endocrinol Metab 80:1086-1089.
13. Griffiths E (1985): Thyrotropin-releasing hormone: Central and endocrine effects. Psychoneuroendocrinology 10:225-235.
14. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
15. Hasle H, Helgestad J, Christensen JK, Jacobsen BB, Kamper J (1995): Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: Long-term follow up with cerebral computed tomography scans and endocrinological studies. Eur J Pediatr 154:24-29.
16. Heal DJ, Pycock CJ, Youdim MBH (1983): Actions of TRH and its analogues on the mesolimbic dopamine system. In Griffiths EC, Bennett EW (eds), Thyrotropin-Releasing Hormone. New York: Raven Press, pp 271-282.
17. Hollister L, Berger P, Ogle F, Arnold F, Johnson A (1974): Protirelin (TRH) in depression. Arch Gen Psychiatry 31:468-470.
18. Huey LY, Janowsky DS, Mandell AJ, Judd LL, Pendery M (1975): Preliminary studies on the use of thyrotropin-releasing hormone in manic states, depression and the dysphoria of alcohol withdrawal. Psychopharmacol Bull 11:24-27.
19. Karlberg BE, Kjellman BF, Kagedal B (1978): Treatment of endogenous depression with oral thyrotropin-releasing hormone and amitriptyline. Acta Psychiatr Scand 58:389-400.
20. Kastin AJ, Ehrensing RH, Schalch DS, Anderson MS (1972): Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone. Lancet ii:740-742.
21. Kellner CH, Post RM, Putman F, et al (1987): Intravenous procaine as a probe of limbic system activity in psychiatric patients and normal controls. Biol Psychiatry 22:1107-1126.
22. Ketter TA, Andreason PJ, George MS, et al (1996): Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry 53:59-69.
23. Kiely W, Adrian A, Lee J, Nicolof FJ (1976): Therapeutic failure of oral thyrotropin-releasing hormone in depression. Psychosom Med 38:233-241.
24. Kirkegaard C, Faber J, Hummer L, Rogowski P (1979): Increased level of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 4:227-235.
25. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R (1991): Advances in drug delivery systems and applications in neurosurgery. Adv Tech Stand Neurosurg 18:143-192.
26. Loosen PT (1985): The TRH-induced TSH response in psychiatric patients: A possible neuroendocrine marker. Psychoneuroendocrinology 10:237-260.
27. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD (1991): Continuous infusion of intrathecal baclofen: Long-term effects on spasticity in spinal cord injury. Paraplegia 29:48-64.
28. Manaker S, Eichen A, Winokur A, Rhodes CH, Rainbow TC (1986): Autoradiographic localization of thyrotropin releasing hormone receptors in human brain. Neurology 36:641-646.
29. Marangell LB, George MS, Callahan AM, et al (in press): Effects of intrathecal thyrotropin-releasing hormone (TRH) in refractory depressed patients. Arch Gen Psychiatry.
30. Metcalf G (1982): Regulatory peptides as a source of new drugs - The clinical prospects for analogues of TRH which are resistant to metabolic degradation. Brain Res 257:389-408.
31. Metcalf G, Dettmar PW, Lynn AG, Brewster D, Havler ME (1981): Thyrotropin-releasing hormone (TRH) analogues show enhanced CNS selectivity because of increased biological stability. Regul Pept 2:277-284.
32. Mitsuma T, Nogimori T (1983): Influence of the route of administration on thyrotropin-releasing hormone concentration in mouse brain. Experientia 39:620-622.
33. Mitsumoto H, Salgado ED, Negroski D, et al (1986): Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 36:152-159.
34. Mountjoy CQ, Price JS, Weller M, Hunter P, Hall R, Dewar JH (1974): A double-blind crossover sequential trial of oral thyrotrophin-releasing hormone in depression. Lancet i:958-960.
35. Munsat TL, Taft J, Jackson IMD (1987a): Pharmacokinetics of intrathecal thyrotropin-releasing hormone. Neurology 37:597-601.
36. Munsat TL, Taft J, Kasdon D (1987b): Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. Neurol Clin 5:159-170.
37. Nemeroff CB, Loosen PT, Bissett G, et al (1978): Pharmacobehavioral effects of hypothalamic peptides in animals and man: Focus on thyrotropin-releasing hormone and neurotensin. Psychoneuroendocrinology 3:279-310.
38. Philpot VB Jr (1993): Thyrotropin-releasing hormone in a patient with bipolar disorder [letter]. J Neuropsychiatry Clin Neurosci 5:349-350,
39. Plotnikoff NP, Prange AJ Jr, Breese GR, Anderson MS, Wilson IC (1972): Thyrotropin-releasing hormone: Enhancement of DOPA activity by a hypothalamic hormone. Science 178: 417-418.
40. Post RM, Weiss SR (1992): Endogenous biochemical abnormalities in affective illness: Therapeutic versus pathogenic. Biol Psychiatry 32:469-484.
41. Post RM, Roy-Byrne PP, Uhde TW (1988): Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 145:844-848.
42. Prager JP, DeSalles A, Wilkinson A, Jacobs M, Csete M (1995): Loin pain hematuria syndrome: Pain relief with intrathecal morphine. Am J Kidney Dis 25:629-631.
43. Prange AJ Jr, Lara PP, Wilson IC, Alltop LB, Breese GR (1972): Effects of thyrotropin-releasing hormone in depression. Lancet 2:999-1002.
44. Ragenbass M, Vozzi C, Tribollet E, Dubois-Dauphin M, Dreifuss J (1990): Thyrotropin-releasing hormone causes direct excitation of dorsal vagal and solitary tract neurones in rat brainstem slices. Brain Res 530:85-90.
45. Simasko S, Horita A (1985): Treatment of rats with the TRH analog MK-771. Neuropharmacology 24:157-165.
46. Stanton TL, Bechman AL, Winokur A (1981): Thyrotropin-releasing hormone effects in the central nervous system: Dependence on arousal state. Science 214:678-681.
47. Suen C, Wilk S (1991): Inhibition of pyroglutamyl peptidase II synthesis by phorbol ester in the retinoblastoma cell. Endocrinology 128:2169-2174.
48. van den Burg W, van Praag HM, Bos ER, Piers DA, van Zanten AK, Doorenbos H (1976): TRH by slow, continuous infusion: An antidepressant? Psychol Med 6:393-397.
49. Winokur A, Utiger RD (1974): Thyrotropin-releasing hormone: Regional distribution in rat brain. Science 185:265-267.
50. Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L (1985): Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Res 358: 191-199.